Compass Q2 net loss $19.9M; CTX-8371 shows deep responses; tovecimig OS readout moves to Q1 2026

Compass Therapeutics, Inc.

Net loss Q2 2025 $19.9M ($0.14/share) vs $13.1M ($0.10/share) in Q2 2024; R&D expenses rose 47% to $16.4M.
Tovecimig Ph2/3 BTC trial met primary endpoint (ORR 17.1% vs 5.3%, p=0.031); OS analysis delayed to Q1 2026 due to fewer deaths.
CTX-8371 Ph1: confirmed PR in NSCLC with 100% target lesion reduction and TNBC with >90% reduction; expansion cohorts planned Q4 2025.
CTX-10726 (PD-1 x VEGF-A) showed superior PD-1 inhibition and tumor control vs ivonescimab preclinically; IND filing on track for Q4 2025.
Cash and marketable securities $101M as of June 30, 2025; expected cash runway into 2027.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.